Literature DB >> 19467798

Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.

Kristin Higgins1, Junzo P Chino, Lawrence B Marks, Neal Ready, Thomas A D'Amico, Robert W Clough, Chris R Kelsey.   

Abstract

PURPOSE: To compare preoperative chemotherapy (ChT) and preoperative chemoradiotherapy (ChT-RT) in operable Stage III non-small-cell lung cancer. METHODS AND MATERIALS: This retrospective study analyzed all patients with pathologically confirmed Stage III (N2) non-small-cell lung cancer who initiated preoperative ChT or ChT-RT at Duke University between 1995 and 2006. Mediastinal pathologic complete response (pCR) rates were compared using a chi-square test. The actuarial overall survival, disease-free survival, and local control were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox regression analysis was also performed.
RESULTS: A total of 101 patients who initiated preoperative therapy with planned resection were identified. The median follow-up was 20 months for all patients and 38 months for survivors. The mediastinal lymph nodes were reassessed after preoperative therapy in 88 patients (87%). Within this group, a mediastinal pCR was achieved in 35% after preoperative ChT vs. 65% after preoperative ChT-RT (p = 0.01). Resection was performed in 69% after ChT and 84% after ChT-RT (p = 0.1). For all patients, the overall survival, disease-free survival, and local control rate at 3 years was 40%, 27%, and 66%, respectively. No statistically significant differences were found in the clinical endpoints between the ChT and ChT-RT subgroups. On multivariate analysis, a mediastinal pCR was associated with improved disease-free survival (p = 0.03) and local control (p = 0.03), but not overall survival (p = 0.86).
CONCLUSION: Preoperative ChT-RT was associated with higher mediastinal pCR rates but not improved survival.

Entities:  

Mesh:

Year:  2009        PMID: 19467798     DOI: 10.1016/j.ijrobp.2009.01.069

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.

Authors:  Shinichi Toyooka; Katsuyuki Kiura; Kazuhiko Shien; Kuniaki Katsui; Katsuyuki Hotta; Susumu Kanazawa; Hiroshi Date; Shinichiro Miyoshi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-12

2.  Perspectives on the effect of nodal downstaging and its implication of the role of surgery in stage IIIA (N2) non-small cell lung cancer.

Authors:  Linda W Martin; Reza J Mehran
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 3.  Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions.

Authors:  Carmen Vallejo Ocańa; Pilar Garrido López; Ignacio Muguruza Trueba
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

Review 4.  The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer.

Authors:  Darren S Bryan; Jessica S Donington
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

5.  Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis.

Authors:  Zuen Ren; Shijie Zhou; Zhidong Liu; Shaofa Xu
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

6.  Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.

Authors:  Chi-Fu Jeffrey Yang; Brian C Gulack; Lin Gu; Paul J Speicher; Xiaofei Wang; David H Harpole; Mark W Onaitis; Thomas A D'Amico; Mark F Berry; Matthew G Hartwig
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-02       Impact factor: 5.209

7.  Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer.

Authors:  Mark F Berry; Mathias Worni; Ricardo Pietrobon; Thomas A D'Amico; Igor Akushevich
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

8.  The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.

Authors:  Joaquim Bosch-Barrera; Carlos García-Franco; Francisco Guillén-Grima; Marta Moreno-Jiménez; José María López-Picazo; Alfonso Gúrpide; José Luis Pérez-Gracia; Javier Aristu; Wenceslao Torre; Jesús García-Foncillas; Ignacio Gil-Bazo
Journal:  Clin Transl Oncol       Date:  2012-07-20       Impact factor: 3.405

9.  Induction chemoradiotherapy versus induction chemotherapy for potentially resectable stage IIIA (N2) non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shaodong Tong; Zhaohui Qin; Minghui Wan; Longzhen Zhang; Yan Cui; Yuanhu Yao
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

10.  Evaluation of prognostic factors in lung cancers with surgical complete response after induction treatment.

Authors:  Mustafa Vedat Doğru; Celal Buğra Sezen; Cemal Aker; Volkan Erdoğu; Özkan Saydam; Aysun Ölçmen; Levent Cansever; Muzaffer Metin
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-04-26       Impact factor: 0.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.